secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009320
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Therapeutics appoints Jan Skvarka to Board of Directors
------------------------------------------------------------------

- Appointed Jan Skvarka, Ph.D., MBA to the Board, effective March 23, 2023.
- Skvarka will serve as a Class I director until the 2025 annual meeting.
- Board determined Skvarka is independent under Nasdaq listing standards.
- Compensation follows Non-Employee Director Compensation Policy; entered indemnification agreement.
- No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023009320/0000950170-23-009320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023009320/glue-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer